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Abstract
Introduction: Although pneumonia has been identified as the single most common risk factor for acute lung
injury (ALI), we have a limited knowledge as to why ALI develops in some patients with pneumonia and not in
others. The objective of this study was to determine frequency, risk factors, and outcome of ALI in patients with
infectious pneumonia.
Methods: A retrospective cohort study of adult patients with microbiologically positive pneumonia, hospitalized at
two Mayo Clinic Rochester hospitals between January 1, 2005, and December 31, 2007. In a subsequent nested
case-control analysis, we evaluated the differences in prehospital and intrahospital exposures between patients
with and without ALI/acute respiratory distress syndrome (ARDS) matched by specific pathogen, isolation site,
gender, and closest age in a 1:1 manner.
Results: The study included 596 patients; 365 (61.2%) were men. The median age was 65 (IQR, 53 to 75) years. In
total, 171 patients (28.7%) were diagnosed with ALI. The occurrence of ALI was less frequent in bacterial (n = 99 of
412, 24%) compared with viral (n = 19 of 55, 35%), fungal (n = 39 of 95, 41%), and mixed isolates pneumonias (n =
14 of 34, 41%; P = 0.002). After adjusting for baseline severity of illness and comorbidities, patients in whom ALI
developed had a markedly increased risk of hospital death (ORadj 9.7; 95% CI, 6.0 to 15.9). In a nested case-control
study, presence of shock (OR, 8.9; 95% CI, 2.8 to 45.9), inappropriate initial antimicrobial treatment (OR, 3.2; 95% CI,
1.3 to 8.5), and transfusions (OR, 4.8; 95% CI, 1.5 to 19.6) independently predicted ALI development.
Conclusions: The development of ALI among patients hospitalized with infectious pneumonia varied among
pulmonary pathogens and was associated with increased mortality. Inappropriate initial antimicrobial treatment
and transfusion predict the development of ALI independent of pathogen.
Introduction
Despite recent improvements in supportive treatment,
acute lung injury (ALI) remains a devastating syndrome,
with pneumonia as the most common predisposing con-
dition [1]. Although recent data demonstrated temporal
improvement in survival, the mortality in ALI patients
still remains high [2,3].
Because therapeutic options are limited and the
majority of intervention strategies are focused on sup-
portive treatment, emphasis has been placed on identify-
ing patients who are at higher risk for ALI [4,5]. Patients
with ALI represent a heterogeneous group of patients
with regard to predisposing conditions [6] that differ in
pathophysiologic changes [7,8], clinical and radiologic
[9] characteristics, as well as treatment options [10,11],
but the data on specific risk factors in subsets of
patients according to predisposing causes are limited.
Although sepsis, particularly pulmonary in origin, is the
most common underlying risk factor for ALI, in only a
small proportion of hospitalized patients with pneumo-
nia does the complication develop (< 10%) [4]. Defining
risk factors associated with the development of ALI in
patients with infectious pneumonia is challenging
because virulence factors of different pathogens have
been implicated in causing lung damage [12,13]. In
patients with pneumonia, the relation between ALI and
specific pathogens has been described mainly in case
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series and case reports of acute respiratory distress syn-
drome (ARDS) in patients with Legionella and certain
types of viral and fungal pneumonia, suggesting that
some pathogens are particularly prone to induce lung
injury. A recent study of critically ill patients demon-
strated that pulmonary infection is associated with a
higher risk of developing ARDS, as compared with
infections at nonpulmonary sites [14]. Systematic data
regarding occurrence, risk factors, and outcome of ALI/
ARDS in patients with infectious pneumonia are lacking.
The objective of the present study was to determine
the frequency and outcome of ALI in a retrospective
cohort of hospitalized patients with microbiology-proven
pneumonia and to identify prehospital and hospital
exposures that may predict the development of ALI,
independent of pathogen.
Materials and methods
We used validated queries of the Mayo Clinic electronic
medical record database (Mayo Clinic Life Sciences Sys-
tem) [15,16] to identify consecutive patients with micro-
biologically positive pneumonia who were hospitalized
at the two Mayo Clinic Rochester hospitals between Jan-
uary 1, 2005, and December 31, 2007. The Institutional
Review Board approved the study protocol and waived
the need for informed consent in this observational
study. To be included in the study, patients had to be at
least 18 years of age and have a diagnosis of pneumonia
with identified pathogens according to the International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation (ICD-9-CM) (ICD codes 480.0-480.8, 481-482.89,
483-484.8, 487.0, 114.0, 115.5, 116.0 and 136.3). If a
patient had more than one episode that met inclusion
criteria, only the first episode was included. Electronic
medical records, including portable digital chest radio-
graphs and microbiology reports, were independently
reviewed to confirm the diagnosis of pneumonia and
pathogen isolation. Pneumonia was defined as a new or
progressive infiltrate as seen on a chest radiograph or
CT scan along with a high clinical suspicion of pneumo-
nia, defined with at least one of the following: fever (>
38°C or > 100.4°F), leukopenia (< 4,000 WBC/mm3) or
leukocytosis (> 12,000 WBC/mm3), altered mental status
with no other recognized cause (for adults older than 70
years), and at least two of the following: (a) new onset
of purulent sputum, or change in character of sputum,
or increased respiratory secretions, or increased suction-
ing requirements, (b) new onset or worsening cough, or
dyspnea, or tachypnea, (c) rales or bronchial breath
sounds, and (d) worsening gas exchange, increased oxy-
gen requirements, or increased ventilation demand
[17,18]. The onset of pneumonia (the time of diagnosis
of pneumonia) was defined by the first recorded time of
any criterion when these criteria were met.
Microbiological etiology
Patients were included if one or more respiratory patho-
gens were recovered from: (a) an uncontaminated speci-
men (blood, pleural fluid, transtracheal aspirate,
transthoracic aspirate, or surgical lung biopsy specimen);
(b) positive serology defined as elevated immunoglobulin
M (IgM) antibodies or fourfold increases in IgG anti-
body titers; (c) positive urinary antigen test; (d) positive
polymerase chain reaction (PCR); (e) semiquantitative
cultures of a lower respiratory tract sample (endotra-
cheal aspirate, bronchoalveolar lavage (BAL), or pro-
tected specimen brush); (f) or expectorated sputum
culture.
We identified ALI patients with a validated electronic
syndrome surveillance tool (ALI “sniffer”) that was
developed for early recognition of patients meeting
inclusion criteria for ARDS-net trials. The negative pre-
dictive value 99.6% (95% CI, 99.3 to 99.8) of the electro-
nic alert had been determined in a previous study
against the gold standard of prospective assessment by
trained intensivist researchers, blinded to the ALI elec-
tronic alert. The details of the ALI electronic alert have
been previously published [16]. All patients with a posi-
tive ALI “sniffer” were reassessed and ALI diagnosed by
an independent review of portable chest radiographs,
arterial blood gases, and hemodynamic parameters
based on American/European consensus conference
definition [19]. For adequate interpretation of radiologic
studies in the diagnosis of ALI, the abstractors reviewed
a structured ALI tutorial before study onset. Interrater
reliability for diagnosing ALI was assessed in previous
studies (kappa value of 0.8) [20]. The timing of ARDS
was determined by the first recorded time of either cri-
terion when both criteria (PaO2/FIO2, bilateral infil-
trates) were met.
To identify the risk factors for ALI development, in a
subsequent nested case-control study, patients who
developed ALI more than 6 hours after pneumonia
onset were matched to patients at risk who did not
develop ALI, based on specific pathogen, isolation site,
gender, and closest age in a 1:1 matching. If an appro-
priate control was not found for a specific pathogen,
matching was for the same genus, family, and finally
pathogen group (G-, G+, atypical bacteria, viruses, and
fungi). Patients with coinfections were matched to
appropriate controls in the same fashion (all pathogens
were matched). Because preliminary data suggested
increased risk of ALI among Pneumocystis jirovecii
pneumonia, these cases were matched to specific patho-
gen, regardless of coinfection. The matching was conser-
vative to provide as perfect as possible matches. Among
171 cases of ALI, 118 were diagnosed with ALI more
than 6 hours after pneumonia onset, of whom 112 were
matched according these criteria. We extracted data
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from the preexisting hospital electronic database, which
included integrated microbiologic and susceptibility
results, vital signs as well as laboratory parameters,
comorbidities, and use of medications. Risk factors were
compared between patients who developed ALI and
matched controls. For quality assurance, we performed
random checks of electronic database entries. Standard
definitions were used for shock [21], inappropriate anti-
microbial treatment [22], and transfusions [23]. We
used the Pneumonia severity index (PSI) [24] to assess
baseline severity of illness and the Charlson score [25]
as a measure of comorbidities. Arterial oxygen satura-
tion measured by pulse oximetry (SpO2) was recorded if
there was a delay in obtaining arterial blood gas analysis,
and the SpO2/FIO2 ratio was used to substitute PaO2/
FIO2 ratio (SpO2/FIO2 < 315 corresponds to PaO2/FIO2
< 300) [26]. To assure similar exposure time to possible
risk factors between cases and controls, the exposure
time for each control was matched to the exposure time
of the corresponding case. That means that data on pos-
sible intrahospital exposures of cases were collected
from onset of pneumonia to onset of ALI, whereas in
controls, data were tabulated for the same number of
hours subsequent to the onset of pneumonia.
We excluded patients with pneumonectomy and venti-
lator-associated pneumonia (VAP). VAP patients were
excluded to eliminate the possibility of including
patients with pneumonia complicating ALI and to limit
effect-cause bias. Patients with potentially contaminated
blood culture (bacteremia cases with a single positive
blood culture of coagulase-negative staphylococci) were
also excluded from the analysis.
Statistical analysis
Continuous variables were compared by using the Stu-
dent t test for normally distributed variables and the
Wilcoxon rank-sum test for nonnormally distributed
variables. The c2 or Fisher exact test was used to com-
pare categoric variables. In a retrospective cohort of
pneumonia patients, the association between pathogens
and ALI occurrence, and ALI and hospital mortality was
assessed in univariate followed by multivariate logistic
regression analysis, after adjusting for baseline severity
of illness. In a subsequent nested case-control study of
112 ALI cases and 112 matched controls, paired para-
metric and nonparametric testing were used as appro-
priate, followed by a conditional logistic regression to
investigate the relation between ALI and specific base-
line characteristics and in-hospital exposures. Selection
of the variables for a conditional logistic regression
model was done, considering both clinical plausibility,
and statistical criteria (significance, colinearity, and
interaction). All P values of < 0.05 were considered to
indicate statistical significance. SAS statistical software
(SAS version 9; SAS Institute, Inc., Cary, NC, USA) was
used for statistical analysis.
Results
Figure 1 shows the flow of study participants. The
cohort included 596 patients; 365 (61.2%) were men.
The median age was 65 (interquartile range (IQR), 53 to
75) years. The etiology of pneumonia was mostly bacter-
ial (n = 412; 69%), followed by fungal (n = 95; 16%),
viral (n = 55; 9%), and mixed pathogens (n = 34; 6%).
Co-infections were present in 131 (22%) cases. The
pathogens were most commonly isolated from sputum
in 206 (28.2%), in tracheal aspirate 151 (20.6%), in
bronchoalveolar lavage (BAL) fluid 126 (17.3%), in blood
92 (12.6%), and in bronchial washings 46 (6.3%).
Baseline characteristics of patients are presented in
Table 1. One hundred and seventy-one patients (28.7%)
were diagnosed with ALI. ALI less commonly occurred
in patients with community-acquired pneumonia (CAP)
(n = 61; 21.8%) compared with those with healthcare-
associated (HCAP) (n = 53; 31.6%; P = 0.02) and hospi-
tal-acquired pneumonias (HAP) (n = 57, 38.5%;
Figure 1 Study flow diagram.
Table 1 Baseline characteristics of the cohort
N = 596
Age, median (IQR) 64.5 (53-75)
Male gender, n (%) 365 (61)
Pneumonia severity index score, median (IQR) 119 (94-146)
Charlson comorbidity score, median (IQR) 2 (1-4)




CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia;
HCAP, healthcare-associated pneumonia; IQR, interquartile range.
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P < 0.001). Among 448 patients who had evidence of
pneumonia at the time of hospital admission, 43 (9.6%)
presented with ALI on admission, of whom 21 (49%)
were transferred from another hospital; in the remain-
der, the median time to development of ALI was 2
(IQR, 1 to 3) days.
The occurrence of ALI was less frequent in bacterial
pneumonias (n = 99 of 412; 24%) compared with viral
(n = 19 of 55; 35%), fungal (n = 39 of 95; 41%), and
mixed isolates pneumonias (n = 14 of 34; 41%) (P =
0.002). Figure 2 displays the frequency of ALI according
to the most common pathogens. Similar results were
obtained when coinfections were excluded from the ana-
lysis. When the analysis was restricted to bacteremic
patients, Gram-positive and Gram-negative bacterial
infections had a similar frequency of ALI (20% versus
15%; p = 0.75). All patients diagnosed with respiratory
syncytial virus (RSV) pneumonia (four of four) devel-
oped ALI. Pneumonia due to Pneumocystis jiroveci and
Blastomyces species was associated with increased risks
of ALI when compared to Streptococcus pneumoniae,
the most common cause of pneumonia, in both univari-
ate (OR, 3.35; 95% CI, 1.5 to 7.61; OR, 4.41; 95% CI, 1.1
to 19.4, respectively) and multivariate analyses (OR, 3.8;
95% CI, 1.65 to 8.93; OR, 5.6; 95% CI, 1.3 to 26.2;
respectively), after adjusting for baseline severity of ill-
ness (pneumonia severity index). Patients who developed
ALI had a markedly increased risk of hospital death in
both univariate (ORadj 9.2; 95% CI, 5.8 to 14.8) and mul-
tivariate analysis after adjusting for baseline severity of
illness and comorbidities (Charlson score) (ORadj 9.7;
95% CI, 6.0 to 15.9).
The association between previously proposed risk fac-
tors for the development of ALI was examined in 112
patients who had no ALI at the time pneumonia was
diagnosed and who were matched by specific pathogen,
age, and gender. The characteristics of ALI cases and
controls are presented in Table 2. Patient groups were
similar in terms of comorbidities expressed as cumula-
tive Charlson score. No difference was found in fre-
quency of diabetes between cases and controls. Patients
who developed ALI were more likely to present with
bilateral infiltrates. Fifty-one patients (45.5%) that pre-
sented with unilateral infiltrate later progressed to ALI.
ALI cases had lower SaO2/FiO2 at the baseline and
higher baseline pneumonia severity index. Most of the
patients with RSV and PCP infections were immunosup-
pressed (30 of 32). The median time to any antibiotic
administration was similar in cases and controls, but
inappropriate initial antimicrobial treatment was asso-
ciated with increased risk of ALI (Table 2). The transfu-
sion of fresh frozen plasma, platelets, and red blood
cells was associated with ALI development.
When adjusted for baseline imbalances (shock, SpO2/
FiO2, type of pneumonia) in a conditional logistic
regression analysis, inappropriate antimicrobial treat-
ment (OR, 3.2; 95% CI, 1.3 to 8.5) and transfusions (OR,
4.8; 95% CI, 1.5 to 19.6) were independently associated
with the development of ALI (Table 3). The results
were similar after adjustment for PSI (as a composite
measure of baseline severity of illness) (Table 4).
Patients who developed ALI were more likely to be
mechanically ventilated, had longer hospital length of
stay, and had a markedly increased risk of hospital
death (Additional file 1). In a post hoc analysis we
explored the association between the prehospital use of
certain medications (statins, ACE inhibitors, and antipla-
telet drugs) that were found to modify development of
ALI in previous studies. When adjusted for adequate
antibiotics, transfusion, and PSI in conditional logistic
regression analysis, the use of a statin was associated
with a decreased risk of ALI (OR, 0.36; 95% CI, 0.14 to
0.92).
Discussion
The results of this study suggest that ALI is common in
hospitalized pneumonia patients with positive microbio-
logic diagnosis. In addition, patients with bacterial pneu-
monia had lower rates of ALI compared with those with
fungal, viral, and mixed infections. When controlled for
age, gender, and specific pathogen, independent predic-
tors of ALI in pneumonia patients are baseline severity
of illness, inappropriate initial antimicrobial treatment,
and transfusion.
Figure 2 Frequency of ALI among the most commonly isolated
pathogens. *Coinfections included.
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66 (59) 52 (46) 1.24 (0.96-1.65) 0.07
Alcohol abuse
n (%)
13 (12) 9 (8) 1.28 (0.74-1.93) 0.37
Pneumonia type 0.007a
n (%)
CAP 33 (29.5) 55 (49) 0.32 (0.15-0.63)
HCAP 33 (29.5) 29 (26) 1.22 (0.66-2.27)
HAP 46 (41) 28 (25) 2.10 (1.19-3.86)
Charlson score
Median (IQR)
3 (2-4) 2 (1-4) 1.0 (0.88-1.14) 0.26
Aspiration n (%) 8 (7.1) 4 (3.6) 1.84 (0.63-6.55) 0.25
Diabetes n (%) 25 (22) 33 (29) 0.71 (0.39-1.26) 0.24
Immunosuppression
n (%)
52 (46.4) 50 (44.6) 1.13 (0.54-2.36) 0.73




1.02 (1.01-1.03) < 0.001 a
Shock n (%) 47 (42) 9 (8) 16.3 (5.47-79.04) < 0.001 a
Respiratory rate
Median (IQR)







0.995 (0.993-0.997 < 0.001 a
Bilateral infiltrates
n (%)
61 (54.5) 31 (38.2) 3.67 (1.92-7.61) < 0.001 a
Pleural effusion
n (%)
23 (20.5) 17 (15.4) 1.34 (0.68-2.69) 0.38
Interventions
Time to antibiotics (hours)
Median (IQR)
0 (0-9) 0 (0-3) 1.00 (0.99-1.02) 0.11
Appropriate initial antimicrobial treatment
n (%)
62 (55.4) 85 (75.9) 0.29 (0.13-0.58) < 0.001 a
Any transfusion
n (%)
38 (33.9) 15 (13.4) 4.53 (2.08-11.59) < 0.001 a
Platelets 15 (13.4) 4 (3.6) 6.50 (1.47-59.33) 0.0098 a
Red blood cells 31 (27.7) 13 (11.6) 4.0 (1.59-11.96) 0.002 a
Fresh frozen plasma 10 (8.9) 1 (0.9) - 0.008 a
Corticosteroids systemic
n (%)
48 (42.9) 51 (45.5) 0.89 (0.51-1.55) 0.67
Mechanical ventilation
n (%)
95 (85) 24 (21) 29.4 (10.2-141.17) < 0.001 a
Invasive 80 (71) 19 (17) 18.36 (7.24-66.69)
Noninvasive 15 (14) 5 (4) 2.83 (1.13-8.25)
BMI, Body mass index; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; IQR, interquartile
range.a
a- statistically significant
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ALI rates in our study were higher compared with a
previous study of hospitalized patients with clinically
defined pneumonia by Ferguson and colleagues (10%)
[4]. This could be due to the inclusion, in our study, of
only patients with a high clinical suspicion of pneumo-
nia and identified isolates, which has been described in
fewer than 50% of hospitalized patients with pneumonia
[27]. In addition, most of our patients had an infectious
agent isolated from lower respiratory tract secretions,
indicating that this population probably represents a
group of more severely ill patients. A recent report of
infection-related ARDS in patients with sepsis, pneumo-
nia, and bacteremia yielded results similar to ours [14].
In our study, the main causes of pneumonia were S.
aureus (with high percentage of MRSA), S. pneumoniae
and Pseudomonas aeruginosa. Similar results were
obtained by Kollef et al. [28]. Among the most common
pathogens, no difference in the rates of ALI was found.
We observed a higher proportion of ALI occurrence in
patients with less common infections due to fungal and
viral respiratory pathogens. The higher rate of ALI
among these pathogen groups likely relates to P. jiroveci,
and specific endemic fungi, including Blastomyces spe-
cies and viral infections (RSV, cytomegalovirus). Possible
explanations for this higher risk include delayed antimi-
crobial treatment, as these pathogens are often not trea-
ted with initial empiric antimicrobial coverage, as well
as baseline characteristics of the patients, because these
infections more commonly occur in those who are
immunocompromised. Progression to ALI is likely a
result of a complex interaction of patient immune status
and specific pathogen [29]. Conversely, when adjusted
for a specific pathogen, immunosupression did not influ-
ence progression to ALI. However, these results must be
interpreted with caution because matching by specific
pathogen is similar to matching by immune status or
other baseline risk factors for these pathogens, which
precludes analyzing the significance of these risk factors
for developing ALI. Unfortunately, our study design
does not allow further assessment of independent effects
of a pathogen on risk for ALI development. Although
numerous reports exist of Legionella pneumonia-
induced ARDS, our study failed to confirm an increased
risk of ALI in these patients. It is possible that early
initiation of empiric antimicrobial coverage for atypical
bacteria, as proposed in current pneumonia guidelines,
has reduced this devastating complication in patients
with Legionella pneumonia. We observed no case of ALI
in the course of pneumonia caused by other “atypical”
bacteria.
Several studies have shown that ALI is rarely present
at the time of hospitalization and usually develops in
hours to days after hospital admission [4,30]. The evolu-
tion of ALI could be influenced by both baseline charac-
teristics of the patients (first hit) as well as a variety of
intrahospital exposures (second hit) [31]. Certain pre-
hospital exposures (alcohol, smoking) [32,33], medical
errors (delayed shock resuscitation, delayed antibiotic
treatment) [30], and iatrogenic exposures (plasma trans-
fusion from alloimmunized donors, gastric aspiration,
certain chemotherapeutic drugs) [23,34,35] have all been
associated with development of ALI in hospitalized
patients. Similar to the results of other studies [35], we
observed higher baseline severity of illness among ALI
cases. Considering baseline characteristics, patients with
ALI were more often smokers, although statistical differ-
ence was not reached. This could be because we used
patients’ histories to obtain information on smoking. In
a recent study by Hsieh [36], serum and urine nicotine
metabolites identified considerably more active smokers
than did smoking history. Active and passive cigarette
smoking was found to be associated with ALI after
severe blunt trauma, when a biomarker of tobacco
smoking was used to assess smoking history [37]. Unlike
several other studies [32,38], the history of alcohol
abuse did not influence the risk of ALI. In addition,
although the majority of studies implicated diabetes to
have a protective role [39,40], no difference in number
of diabetics was found between the cases and controls
in our study.
The highest percentage of ALI was found among
patients with healthcare-associated pneumonia (HCAP)
and hospital-acquired pneumonia (HAP), suggesting
that health-care-related exposures could have contribu-
ted to the development of ALI. When matched for age,
gender, and pathogen characteristics, and adjusted for
baseline severity of illness, the major interventions that
were associated with an increased risk of ALI were
transfusions and inappropriate initial antimicrobial ther-
apy. Previous studies demonstrated an increased risk of




Inappropriate initial antimicrobial treatment 3.2 1.3-8.5
Any transfusion 4.8 1.5-19.6
HAP 1.9 0.8-4.5
HAP, hospital-acquired pneumonia.
Table 4 Conditional regression analysis of ALI risk factors
OR 95% CI
PSI 1.01 1.00-1.03
Inappropriate initial antimicrobial treatment 3.1 1.5-7.0
Any transfusion 3.2 1.3-8.8
HAP 1.8 0.9-3.8
HAP, hospital-acquired pneumonia; PSI, pneumonia severity index.
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ALI in patients with delayed treatment of infection [30].
The time of antibiotic initiation did not influence ALI
development in our study, as most patients received
antibiotics in the emergency department or immediately
after admission; however, ALI was associated with inap-
propriate initial antimicrobial therapy. In patients with
pneumonia, inappropriate initial antibiotic treatment
noticeably increases the risk of hospital death [41,42].
The failure to provide adequate antibiotic treatments is
more likely in HCAP and HAP, as Gram-negative bac-
teria and S. aureus are major pathogens in these patients
[28]. In addition to antimicrobial resistance [41], it
seems that patients with HCAP are often not empirically
treated for these organisms, resulting in suboptimal
antibiotic therapy and increased mortality [43].
Although shock was clearly associated with ALI devel-
opment, the association of delayed goal-directed resusci-
tation could not be examined because of a relatively low
number of shock patients among controls. The observed
association between transfusion and lung injury has
been demonstrated in number of studies [40,44,45]. The
observed association between the use of statins and the
decreased risk of ALI is consistent with the recent
report by O’Neal et al. [46]. Contrary to a previous
report in a population-based cohort of nonselected
patients at risk of ALI [47], the use of antiplatelet agents
in patients with infectious pneumonia was not asso-
ciated with decreased risk of ALI.
Severe pneumonia is associated with high rates of
morbidity and mortality [48-51]. The majority of these
studies failed to account for ALI as well as its role in
the course of pneumonia and patient outcomes. Our
work demonstrated that the development of ALI is inde-
pendently associated with increased mortality after
adjusting for baseline severity of illness and comorbid-
ities. This is particularly important because multiple fac-
tors influence ALI development and are potential targets
for preventing this devastating syndrome.
Our study has several limitations. First, enrollment was
limited to microbiologically proven pneumonia. Because
the majority of patients with pneumonia do not undergo
any microbial testing, some patients with pneumonia were
excluded and may have biased our study population to
more severe cases that underwent such evaluation. Diag-
nosis of atypical pneumonia is difficult because of the fas-
tidious nature of atypical organisms; the sensitivity of
cultures is low, serologic assays are poorly standardized
[52], and PCR is not generally available [27]. Because only
semiquantitative analysis of lower respiratory secretions
were available, differentiation between microbiologically
definite and probable pneumonia was not possible in all
patients. Conversely, because ALI/ARDS also has nonin-
fectious etiologies (aspiration, organizing pneumonia,
transfusion-induced lung injury (TRALI), acute
eosinophilic pneumonia, diffuse alveolar hemorrhage, and
other interstitial lung diseases), we believe that isolation of
a microbiologic agent strengthened the diagnosis of infec-
tious pneumonia and prevented the inclusion of noninfec-
tious lung diseases that might have been included by using
only the clinical definition.
Second, because we matched by pathogen, we could
not properly examine the influence of specific pathogen
and immune status on ALI development. It is likely that
the results would be different for specific viral (RSV,
CMV) or fungal (PCP) pathogens, but limited control
data precludes the analysis (because clinicians rarely test
immunocompetent patients for these pathogens). Con-
versely, matching by specific pathogen supports the
findings that inappropriate antimicrobial treatment is an
independent predictor of ALI and not just a marker of
having an atypical pathogen.
Third, differentiation between severe bilateral pneu-
monia and ALI/ARDS may be challenging. Sensitivity
and specificity of clinical assessment compared with a
pathologic finding of diffuse alveolar damage (DAD) was
found to be poor, with the weakest correlation in pneu-
monia patients [53].
Fourth, we used the pneumonia severity index as a
composite measure of baseline severity of illness in all
patients. The PSI has been validated in CAP and HCAP
but not HAP patients. However, the results were similar
when adjusted for baseline imbalances (shock, SpO2/
FiO2) instead of PSI.
Finally, a limitation of our study is inherent in its ret-
rospective design.
Conclusions
In conclusion, to our knowledge, this is the first study to
assess the relation between ALI and specific respiratory
pathogens isolated from patients with pneumonia. The
results show that patients with confirmed infectious
pneumonia are at a high risk of ALI, especially those
with certain types of fungal and viral pneumonias. No
difference was found in the occurrence of ALI among
the most common bacterial pathogens, suggesting other
possible mechanisms that may promote the develop-
ment of ALI, aside from pathogen characteristics. Poten-
tially modifiable health-care delivery factors such as
antibiotic therapy and transfusion pose significant risk
and provide important targets for ALI prevention.
Key messages
• ALI development is common among hospitalized
pneumonia patients with positive microbiology.
• The development of ALI among patients hospita-
lized with infectious pneumonia varies among pul-
monary pathogens and is associated with increased
mortality.
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• Inappropriate initial antimicrobial treatment and
transfusion of blood products are modifiable inde-
pendent predictors of ALI development in pneumo-
nia patients.
Additional material
Additional file 1: Outcomes of ALI cases and matched controls.
Table describing the differences in hospital length of stay, duration of
mechanical ventilation, and hospital mortality between ALI cases and
matched controls.
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